Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03600441 · ClinicalTrials.gov registry record · Phase 2
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
A Phase 2 study of Follicular Lymphoma, sponsored by Xynomic Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 139
- Enrollment target
- 15
- Study locations
NCT03600441: Active Phase 2 study of Follicular Lymphoma, sponsored by Xynomic Pharmaceuticals.
NCT03600441 is a Phase 2 study of Follicular Lymphoma that is active but no longer recruiting, run by Xynomic Pharmaceuticals. The registered enrollment target is 139 participants, roughly in line with the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target. The trial reports 15 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03600441, a Phase 2 study of Follicular Lymphoma, is active but no longer recruiting, sponsored by Xynomic Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 139 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off" schedule.
Primary Outcome
Complete response (CR) or partial response (PR) according to the Lugano 2014 criteria as determined by an Independent Review Committee (IRC).
Conditions Studied
Interventions
- DRUG Abexinostat
Study Locations (15)
Other
- Hospital Universitario Vall d'Hebrón - Barcelona
- Hospital del Mar - Barcelona
- C.H. Regional Reina Sofia - Córdoba
- Hospital Universitario Infanta Leonor - Madrid
New York
- Clinical Research Alliance Inc - Lake Success
- Manhattan Hematology Oncology Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- Arlington Cancer Center - Arlington
- Central Texas Veterans Health Care System - NAVREF - Temple
Illinois
- Advocate Medical Group - Park Ridge, Luther Lane - Oncology - Park Ridge
Kentucky
- Norton Cancer Institute - St. Matthews Campus - Louisville
Pennsylvania
- Bone Marrow Transplant Hematology Oncology Associates - Pittsburgh
Washington
- Vista Oncology Inc. PS - Olympia
Pyrénées-Orientales
- Centre Hospitalier de Perpignan - Perpignan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2018-08-27 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
What the registry record for NCT03600441 still lists
NCT03600441 is an interventional study that assigns participants to a tested intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target.
The record links to 1 condition, with Follicular Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Abexinostat is the first listed.
NCT03600441 lists 15 locations in 9 states (Other, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT03600441 about?
NCT03600441 is a clinical study titled "Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma". This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off" schedule.
What is the current status of trial NCT03600441?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 139 participants. The study started on 2018-08-27. Estimated completion is 2029-12-31.
What conditions does trial NCT03600441 study?
This clinical trial studies the following conditions: Follicular Lymphoma.
What interventions are being tested in trial NCT03600441?
The interventions under investigation include: Abexinostat (DRUG).
Who is sponsoring clinical trial NCT03600441?
This trial is sponsored by Xynomic Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03600441 being conducted?
This trial has 15 study locations across Illinois, Kentucky, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03600441's enrollment target sits among peer trials
139 25th of 89 higher than 65 of 89 other Follicular Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Follicular Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645380 · 139 participants · Phase 2
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- NCT06239272 · 139 participants · Phase 1
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- NCT06252220 · 139 participants · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
- NCT06537128 · 139 participants · NA
Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI